ArticleCancers2025

Real World Data on the Efficacy of Brigatinib in ALK-Positive Non-Small Cell Lung Cancer: A Single-Center Experience.

Vesna Ćeriman Krstić et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.